Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4637) 4637
Government Document (449) 449
Publication (419) 419
Book / eBook (123) 123
Book Chapter (33) 33
Book Review (21) 21
Newspaper Article (14) 14
Dissertation (4) 4
Magazine Article (4) 4
Conference Proceeding (3) 3
Reference (3) 3
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4312) 4312
male (3443) 3443
female (3133) 3133
middle aged (2493) 2493
adult (2301) 2301
vital capacity (2240) 2240
respiratory system (1680) 1680
aged (1672) 1672
forced expiratory volume (1578) 1578
index medicus (1482) 1482
vital capacity - drug effects (1473) 1473
forced expiratory volume - drug effects (857) 857
adolescent (828) 828
spirometry (770) 770
asthma (746) 746
asthma - physiopathology (738) 738
asthma - drug therapy (693) 693
double-blind method (679) 679
treatment outcome (642) 642
lung - physiopathology (630) 630
vital capacity - physiology (593) 593
time factors (578) 578
child (516) 516
lung - drug effects (515) 515
administration, inhalation (500) 500
pulmonary disease, chronic obstructive - physiopathology (488) 488
respiratory function tests (467) 467
forced expiratory volume - physiology (465) 465
research (456) 456
cardiac & cardiovascular systems (389) 389
copd (388) 388
bronchodilator agents - therapeutic use (387) 387
lung diseases, obstructive (379) 379
care and treatment (378) 378
mortality (371) 371
pulmonary disease, chronic obstructive - drug therapy (363) 363
statistical data: health and vital statistics (362) 362
chronic obstructive pulmonary disease (360) 360
risk factors (353) 353
prospective studies (349) 349
respiratory tract diseases (333) 333
obstructive pulmonary-disease (329) 329
aged, 80 and over (325) 325
dose-response relationship, drug (319) 319
analysis (318) 318
drug therapy (317) 317
bronchodilator agents - administration & dosage (316) 316
health aspects (311) 311
children (308) 308
disease (289) 289
pulmonary and respiratory medicine (289) 289
severity of illness index (289) 289
medical research (287) 287
aerosols (285) 285
retrospective studies (285) 285
pulmonary/respiratory (270) 270
lung-function (268) 268
diagnosis (265) 265
respiration - drug effects (264) 264
young adult (260) 260
studies (259) 259
critical care medicine (257) 257
lungs (257) 257
quality of life (254) 254
clinical trials as topic (247) 247
smoking (243) 243
follow-up studies (242) 242
medicine, general & internal (241) 241
disease progression (236) 236
lung diseases (235) 235
inflammation (231) 231
peak expiratory flow rate (220) 220
surveys and questionnaires (220) 220
pulmonary disease, chronic obstructive - diagnosis (217) 217
cross-sectional studies (209) 209
patients (207) 207
albuterol - therapeutic use (205) 205
lung diseases, obstructive - physiopathology (204) 204
physiological aspects (203) 203
animals (200) 200
lung diseases, obstructive - drug therapy (200) 200
oxygen - blood (197) 197
vital statistics (194) 194
forced vital capacity (193) 193
bronchial provocation tests (191) 191
drug therapy, combination (190) 190
public, environmental & occupational health (190) 190
airway resistance - drug effects (188) 188
cross-over studies (187) 187
abridged index medicus (184) 184
pediatrics (184) 184
exercise (182) 182
heart rate - drug effects (181) 181
allergy (179) 179
prevalence (177) 177
pulmonary-function (176) 176
population (174) 174
lung - physiology (173) 173
medicine (171) 171
public health (170) 170
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (54) 54
Gerstein Science - Stacks (38) 38
UTL at Downsview - May be requested (22) 22
UofT at Mississauga - Stacks (19) 19
Collection Dvlpm't (Acquisitions) - Closed Orders (7) 7
OISE - Stacks (7) 7
UofT at Scarborough - Stacks (7) 7
Online Resources - Online (3) 3
St. Michael's College (John M. Kelly) - 2nd Floor (3) 3
Trinity College (John W Graham) - Stacks (3) 3
Victoria University E.J. Pratt - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
New College (Ivey) - Stacks (2) 2
OISE - Reference (2) 2
Providence Healthcare - Stacks (2) 2
Toronto East General Hospital - Stacks (2) 2
Victoria University Emmanuel College - Stacks (2) 2
Baycrest Hospital - Resident/Client Library (1) 1
Baycrest Hospital - Stacks (1) 1
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
New College (Ivey) - Withdrawn (1) 1
OISE - Curriculum Resources (1) 1
Physics - Stacks (1) 1
Robarts - Government Pubs (1) 1
Scarborough Hospital - General (1) 1
Stacks (1) 1
Sunnybrook Health Sciences Centre - Holland Stacks (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
Trinity College (John W Graham) - Special Collections (1) 1
University College (Laidlaw) - Atlases (1) 1
UofT at Mississauga - Reference (1) 1
UofT at Scarborough - Withdrawn (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5047) 5047
German (79) 79
French (31) 31
Polish (22) 22
Italian (17) 17
Spanish (17) 17
Russian (15) 15
Chinese (12) 12
Japanese (7) 7
Czech (6) 6
Danish (3) 3
Croatian (2) 2
Portuguese (2) 2
Slovak (2) 2
Bulgarian (1) 1
Dutch (1) 1
Hebrew (1) 1
Hungarian (1) 1
Icelandic (1) 1
Norwegian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
by King, Talmadge E and Bradford, Williamson Z and Castro-Bernardini, Socorro and Fagan, Elizabeth A and Glaspole, Ian and Glassberg, Marilyn K and Gorina, Eduard and Hopkins, Peter M and Kardatzke, David and Lancaster, Lisa and Lederer, David J and Nathan, Steven D and Pereira, Carlos A and Sahn, Steven A and Sussman, Robert and Swigris, Jeffrey J and Noble, Paul W and ASCEND Study Grp and ASCEND Study Group
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 22, pp. 2083 - 2092
In this randomized, controlled trial, the use of pirfenidone in patients with idiopathic pulmonary fibrosis led to a slower rate of loss in forced vital... 
MORTALITY | SURVIVAL | MEDICINE, GENERAL & INTERNAL | DISTANCE | PREDICTOR | INTERSTITIAL PNEUMONIA | HISTOLOGIC PATTERN | FORCED VITAL CAPACITY | Enzyme Inhibitors - adverse effects | Antifibrinolytic Agents - therapeutic use | Double-Blind Method | Administration, Oral | Humans | Middle Aged | Male | Treatment Outcome | Antifibrinolytic Agents - adverse effects | Disease Progression | Enzyme Inhibitors - administration & dosage | Vital Capacity - drug effects | Idiopathic Pulmonary Fibrosis - mortality | Aged, 80 and over | Adult | Female | Aged | Idiopathic Pulmonary Fibrosis - physiopathology | Pyridones - therapeutic use | Idiopathic Pulmonary Fibrosis - drug therapy | Pyridones - adverse effects | Pulmonary fibrosis | Analysis | Anti-arrhythmia drugs | Clinical trials | Pharmacology | Research | Drug therapy | Dyspnea | Lung diseases | Fibrosis | Death | Skin | Respiration | Survival | Patients | Pharmaceuticals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Forced Vital Capacity in Idiopathic Pulmonary Fibrosis — FDA Review of Pirfenidone and Nintedanib
by Karimi-Shah, Banu A and Chowdhury, Badrul A
The New England Journal of Medicine, ISSN 0028-4793, 03/2015, Volume 372, Issue 13, pp. 1189 - 1191
In 2014, the FDA approved two drugs for idiopathic pulmonary fibrosis that posed a regulatory challenge: the primary efficacy variable studied was the change... 
MEDICINE, GENERAL & INTERNAL | United States | Humans | Enzyme Inhibitors - pharmacology | Drug Approval | Enzyme Inhibitors - therapeutic use | Cause of Death | Advisory Committees | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Vital Capacity - drug effects | Idiopathic Pulmonary Fibrosis - mortality | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Indoles - pharmacology | Indoles - therapeutic use | Idiopathic Pulmonary Fibrosis - physiopathology | Pyridones - therapeutic use | Idiopathic Pulmonary Fibrosis - drug therapy | Pyridones - pharmacology | United States Food and Drug Administration | Studies | Pulmonary fibrosis | Mortality | Lung diseases | Fibrosis | FDA approval | Drug therapy | Pharmaceuticals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
by Richeldi, Luca and du Bois, Roland M and Raghu, Ganesh and Azuma, Arata and Brown, Kevin K and Costabel, Ulrich and Cottin, Vincent and Flaherty, Kevin R and Hansell, David M and Inoue, Yoshikazu and Kim, Dong Soon and Kolb, Martin and Nicholson, Andrew G and Noble, Paul W and Selman, Moisés and Taniguchi, Hiroyuki and Brun, Michèle and Le Maulf, Florence and Girard, Mannaïg and Stowasser, Susanne and Schlenker-Herceg, Rozsa and Disse, Bernd and Collard, Harold R and INPULSIS Trial Investigators
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 22, pp. 2071 - 2082
In this randomized, placebo-controlled trial, treatment with nintedanib, an intracellular inhibitor of multiple tyrosine kinases, led to a reduced rate of loss... 
RESPIRATORY QUESTIONNAIRE | INTERSTITIAL PNEUMONIA | MEDICINE, GENERAL & INTERNAL | TYROSINE KINASE INHIBITOR | ACUTE EXACERBATION | Enzyme Inhibitors - adverse effects | Double-Blind Method | Humans | Middle Aged | Male | Treatment Outcome | Protein Kinase Inhibitors - adverse effects | Disease Progression | Indoles - administration & dosage | Enzyme Inhibitors - administration & dosage | Vital Capacity - drug effects | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Quality of Life | Female | Aged | Idiopathic Pulmonary Fibrosis - physiopathology | Idiopathic Pulmonary Fibrosis - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Complications and side effects | Dosage and administration | Pulmonary fibrosis | Research | Drug therapy | Anti-arrhythmia drugs | Tyrosine | Biopsy | Lung diseases | Fibrosis | Clinical trials | Diarrhea | Vascular endothelial growth factor | Patients
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
by Noble, Paul W, Prof and Albera, Carlo, Prof and Bradford, Williamson Z, MD and Costabel, Ulrich, Prof and Glassberg, Marilyn K, MD and Kardatzke, David, PhD and King, Talmadge E, Prof and Lancaster, Lisa, MD and Sahn, Steven A, Prof and Szwarcberg, Javier, MD and Valeyre, Dominique, Prof and du Bois, Roland M, Prof and CAPACITY Study Grp and CAPACITY Study Group
Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9779, pp. 1760 - 1769
Summary Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable loss of lung function. The CAPACITY programme (studies... 
Internal Medicine | SURVIVAL | LUNG FIBROSIS | MEDICINE, GENERAL & INTERNAL | BLEOMYCIN HAMSTER MODEL | GENE-EXPRESSION | NECROSIS-FACTOR-ALPHA | TRANSCRIPTIONAL LEVEL | PLACEBO-CONTROLLED TRIAL | Follow-Up Studies | Administration, Oral | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Dose-Response Relationship, Drug | Vital Capacity - drug effects | Disease-Free Survival | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Idiopathic Pulmonary Fibrosis - mortality | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Female | Aged | Pyridones - therapeutic use | Idiopathic Pulmonary Fibrosis - drug therapy | Pyridones - adverse effects | Usage | Care and treatment | Pulmonary fibrosis | Diagnosis | Research | Health aspects | Antifibrinolytic agents | Studies | Clinical trials | Lungs | Lung diseases | Regulatory approval | antiinflammatory agents | Respiratory function | Lung | Mortality | Anti-Inflammatory Agents, Non-Steroidal | Pyridones | Idiopathic Pulmonary Fibrosis | Life Sciences | Vital Capacity | Human health and pathology | Pulmonology and respiratory tract
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
by Nathan, Steven D and Albera, Carlo and Bradford, Williamson Z and Costabel, Ulrich and du Bois, Roland M and Fagan, Elizabeth A and Fishman, Robert S and Glaspole, Ian and Glassberg, Marilyn K and Glasscock, Kenneth F and King, Talmadge E and Lancaster, Lisa and Lederer, David J and Lin, Zhengning and Pereira, Carlos A and Swigris, Jeffrey J and Valeyre, Dominique and Noble, Paul W and Wells, Athol U
Thorax, ISSN 0040-6376, 05/2016, Volume 71, Issue 5, pp. 429 - 435
BackgroundThe assessment of treatment response in idiopathic pulmonary fibrosis (IPF) is complicated by the variable clinical course. We examined the... 
Dose-Response Relationship, Drug | Vital Capacity - drug effects | Disease-Free Survival | Idiopathic Pulmonary Fibrosis - mortality | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Humans | Kaplan-Meier Estimate | Treatment Outcome | Pyridones - therapeutic use | Research Design | Disease Progression | Idiopathic Pulmonary Fibrosis - drug therapy | Clinical trials | Care and treatment | Usage | Pulmonary fibrosis | Studies | Population | Trends | Mortality | Regulatory approval | Interstitial Lung Disease | 1506 | Idiopathic pulmonary fibrosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial
by Martinez, Fernando J, Prof and Calverley, Peter M A, Prof and Goehring, Udo-Michael, MD and Brose, Manja, MSc and Fabbri, Leonardo M, Prof and Rabe, Klaus F, Prof
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9971, pp. 857 - 866
Summary Background Roflumilast reduces exacerbations in patients with severe chronic obstructive pulmonary disease. Its effect in patients using fixed... 
Internal Medicine | PROPIONATE | MODERATE | MEDICINE, GENERAL & INTERNAL | INHIBITOR ROFLUMILAST | PLACEBO | INHALED CORTICOSTEROIDS | DOUBLE-BLIND | PREVENTION | N-ACETYLCYSTEINE | COPD | BRONCHODILATORS | Bronchodilator Agents - therapeutic use | Glucocorticoids - therapeutic use | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Aminopyridines - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Cyclopropanes - adverse effects | Cyclopropanes - therapeutic use | Vital Capacity - drug effects | Benzamides - therapeutic use | Aminopyridines - therapeutic use | Phosphodiesterase 4 Inhibitors - adverse effects | Adrenergic beta-2 Receptor Agonists - therapeutic use | Adult | Female | Drug Therapy, Combination | Benzamides - adverse effects | Double-Blind Method | Phosphodiesterase 4 Inhibitors - therapeutic use | Treatment Outcome | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Aged | Pulmonary Disease, Chronic Obstructive - drug therapy | Chronic diseases | Clinical trials | Care and treatment | Lung diseases, Obstructive | Corticosteroids | Chronic obstructive pulmonary disease | Inhibitor drugs | Drug therapy | Drug dosages | Mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis a randomized clinical trial
by Raghu, Ganesh and Van Den Blink, Bernt and Hamblin, Mark J and Whitney Brown, A and Golden, Jeffrey A and Ho, Lawrence A and Wijsenbeek, Marlies S and Vasakova, Martina and Pesci, Alberto and Antin-Ozerkis, Danielle E and Meyer, Keith C and Kreuter, Michael and Santin-Janin, Hugues and Mulder, Geert-Jan and Bartholmai, Brian and Gupta, Renu and Richeldi, Luca
JAMA - Journal of the American Medical Association, ISSN 0098-7484, 06/2018, Volume 319, Issue 22, pp. 2299 - 2307
IMPORTANCE Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with poor prognosis. Approved therapies do not halt disease progression.... 
IMPORTANT DIFFERENCE | MORTALITY | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | SERUM-AMYLOID-P | Recombinant Proteins - therapeutic use | Double-Blind Method | Humans | Middle Aged | Male | Recombinant Proteins - adverse effects | Recombinant Proteins - pharmacology | Serum Amyloid P-Component - adverse effects | Vital Capacity - drug effects | Homeodomain Proteins - adverse effects | Homeodomain Proteins - therapeutic use | Serum Amyloid P-Component - therapeutic use | Serum Amyloid P-Component - pharmacology | Least-Squares Analysis | Female | Aged | Idiopathic Pulmonary Fibrosis - physiopathology | Homeodomain Proteins - pharmacology | Walk Test | Idiopathic Pulmonary Fibrosis - drug therapy | Usage | Care and treatment | Pulmonary fibrosis | Analysis | Placebos | Research | Comparative analysis | Recombinant proteins | Lung volume measurements | Respiratory function | Intravenous administration | Abnormalities | Lung diseases | Medical services | Clinical trials | Fatigue | Rhinopharyngitis | Patients | Placebo effect | Cough | Proteins | Randomization | Computed tomography | Safety engineering | Fibrosis | Least squares | Carbon monoxide | Pentraxins | Predictive control | Recombinant | Online First | Preliminary Communication
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis
by Martinez, Fernando J and De Andrade, Joao A and Anstrom, Kevin J and King Jr, Talmadge E and Raghu, Ganesh and The Idiopathic Pulmonary Fibrosis Clinical Research Network and Idiopathic Pulm Fibrosis Clinical and Idiopathic Pulmonary Fibrosis Clinical Research Network
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 22, pp. 2093 - 2101
Acetylcysteine, which has been advocated as a treatment for patients with idiopathic pulmonary fibrosis, showed no benefit over placebo with respect to loss of... 
SAMPLE-SIZE | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | Azathioprine - therapeutic use | Prednisone - adverse effects | Double-Blind Method | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Disease Progression | Acetylcysteine - adverse effects | Vital Capacity - drug effects | Idiopathic Pulmonary Fibrosis - mortality | Treatment Failure | Female | Aged | Free Radical Scavengers - therapeutic use | Idiopathic Pulmonary Fibrosis - physiopathology | Acetylcysteine - therapeutic use | Drug Therapy, Combination | Azathioprine - adverse effects | Free Radical Scavengers - adverse effects | Idiopathic Pulmonary Fibrosis - drug therapy | Prednisone - therapeutic use | Clinical trials | Acetylcysteine | Pulmonary fibrosis | Research | Drug therapy | Analysis | Statistical analysis | Preservation | Lung diseases | Fibrosis | Prednisone | Azathioprine | Patients
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights